Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.55 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | RXRA | P19793 | 1/20 | 0.50 |
| ▸ | RXRB | P28702 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1549250 | 0.88 | MAOB (0.68) | MAOBMAOAHRH3APP | |
| SCHEMBL9946057 | 0.86 | MAOB (0.60) | MAOBMAOAMRGPRX4IDO1 | |
| SCHEMBL12182456 | 0.84 | MAOB (0.74) | MAOBMAOAHRH3APP | |
| SCHEMBL9946031 | 0.84 | MAOB (0.64) | MAOBMAOAAPP | |
| SCHEMBL15472276 | 0.84 | MAOB (0.60) | MAOBMAOARXRARXRBMRGPRX4 | |
| SCHEMBL24726361 | 0.83 | ALDH1A1 (0.59) | MAOBMAOAHRH3APP | |
| SCHEMBL13483792 | 0.83 | MAOB (0.61) | MAOBMAOARXRARXRBHRH3 | |
| SCHEMBL1702528 | 0.83 | MAOB (0.62) | MAOBMAOAHRH3APP | |
| SCHEMBL15472341 | 0.83 | MAOB (0.61) | MAOBMAOAMRGPRX4 | |
| SCHEMBL4638967 | 0.83 | MAOB (0.66) | MAOBMAOARXRARXRBMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | MAOB 780/4885MAOA 809/4885RXRA 1479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.